LAB
Standard BioTools Inc.
LAB trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over LAB overall, supported by stronger fundamentals.
LAB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Unavailable |
LAB's profitability is currently stable, but its revenue and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.9x | $0.65 | — |
| Cheap | 2.9x | $0.98 | +51% |
| Fair | 3.6x | $1.21 | +86% |
| Expensive | 4.7x | $1.61 | +147% |
Historical ranges are pointers, not guarantees.
LAB has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
LAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect LAB's losses to grow, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over LAB on the outlook, with more favorable earnings and profitability expectations.
LAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.34 | +$0.65 |
| Q2 2026 | $0.22 | +$0.51 |
| Q1 2026 | $0.20 | +$0.52 |
| Q4 2025 | -$0.20 | +$0.32 |
| Q3 2025 | -$0.31 | +$0.39 |
| Q2 2025 | -$0.29 | +$0.61 |
| Q1 2025 | -$0.32 | +$0.68 |
| Q4 2024 | -$0.52 | +$0.42 |
LAB has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
LAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.4M | -0.9% |
| Q2 2026 | $20.1M | -7.6% |
| Q1 2026 | $21.1M | -48% |
| Q4 2025 | $23.8M | -49% |
| Q3 2025 | $19.6M | -57% |
| Q2 2025 | $21.8M | -42% |
| Q1 2025 | $40.8M | -10% |
| Q4 2024 | $46.7M | +66% |
LAB's revenue has slid since its 2024 peak: $19M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -102% | +67 points |
| Q2 2026 | -126% | -8.2 points |
| Q1 2026 | -59% | +22 points |
| Q4 2025 | -104% | -33 points |
| Q3 2025 | -168% | -98 points |
| Q2 2025 | -118% | +18 points |
| Q1 2025 | -81% | +51 points |
| Q4 2024 | -70% | +5.6 points |
LAB's operating margin was −102% last quarter, up 66 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LAB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over LAB on profitability, with a higher operating margin.
LAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.2M | +$16.9M |
| Q2 2026 | -$10.7M | +$11.9M |
| Q1 2026 | -$47.2M | -$11.8M |
| Q4 2025 | -$1.7M | +$15.8M |
| Q3 2025 | -$23.1M | +$7M |
| Q2 2025 | -$22.6M | +$18.4M |
| Q1 2025 | -$35.3M | +$27.9M |
| Q4 2024 | -$17.4M | -$3.3M |
LAB has burned cash in almost every quarter: −$66M over the past year, against −$98M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over LAB on cash generation, producing positive trailing cash flow while its opponent burns cash.
LAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +2.7M shares |
| 1 year | +2.9% | +10.9M shares |
| 3 years | +397% | +314M shares |
| 5 years | +416% | +317M shares |
| Available history | +489% | +327M shares |
LAB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $29.4M |
| Q1 2024 | $11.1M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LAB Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
LAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 16.7 | Oversold |
LAB's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LAB PE vs Healthcare Sector
| Metric | LAB | Sector median | Relative |
|---|---|---|---|
| PE | 1.9x | 26x | 93% below |
| PE % | 4 | 29 | 25 pts below |
LAB has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.66 | 1.5% below |
| 20 week MA | $0.74 | 12% below |
| 50 week MA | $0.97 | 33% below |
| 100 week MA | $1.14 | 43% below |
| 200 week MA | $1.66 | 61% below |
LAB is in a downtrend: it's below all five of its weekly moving averages, and 61% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LAB on trend strength, trading above more of its moving averages.
LAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.36 | $6.48 | +93% |
| 2021 | $6.48 | $3.80 | -41% |
| 2022 | $3.80 | $1.35 | -64% |
| 2023 | $1.35 | $2.21 | +64% |
| 2024 | $2.21 | $1.82 | -18% |
| 2025 | $1.82 | $1.38 | -24% |
| 2026 YTD | $1.38 | $0.65 | -53% |
LAB has finished lower in four of the last six years. It's down 53% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LAB on returns for 2026, with the stronger performance.